https://www.selleckchem.com/pr....oducts/PF-2341066.ht
This study aimed to determine the prevalence of ANCA positivity in children managed with levamisole as a steroid-sparing agent for nephrotic syndrome (NS). Medical records of children with steroid-sensitive NS managed with levamisole therapy at Sydney Children's Hospital between 1/1/2000 and 31/12/2018 were retrospectively reviewed. Main outcome measure was side effects of levamisole therapy including ANCA positivity. Seventy-one children, median age 3years and 1month (IQR 29-68months) at first presentation, were subsequently managed
Like
Comment
Share
